Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.
A new study published on the medRxiv* preprint server analyzed the trajectories of anti-SARS-CoV-2 antibodies in patients from the RituxiVac study were compared to healthy volunteers. In addition, they investigated the immunogenicity of a third vaccine dose in previously non-responding patients.
The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented online at ASN Kidney Week 2021 November 4–November 7.
Younger patients with specific genetic subtypes of non-GCB DLBCL, called MCD and N1, had an exceptional response to the treatment combination.
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like rheumatoid arthritis) were able to produce antibodies against COVID-19 (seroconvert) after receiving a third COVID-19 vaccine dose, even if there was no development of the antibody after the first two doses of the vaccine.
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that in one study, the majority of rheumatoid arthritis patients on an ultra-low dose of the drug rituximab maintained low disease activity for up to four years, and rarely needed to switch to other biologic drugs or glucocorticoids to control their disease.
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that the COVID-19 vaccine was not associated with severe disease flares in patients with rheumatic diseases.
A new study posted to the medRxiv* preprint server studies the neutralizing antibody response in cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non-Hodgkin’s lymphomas (NHL), post-reception of two doses of messenger RNA (mRNA) vaccines.
A clinical study by a team of scientists from Norway aimed to assess the immunogenicity and safety of a third dose of COVID-19 mRNA vaccine in MS patients treated with anti-CD20 therapy or fingolimod. A preprint version of the study, which is yet to undergo peer review, is available on the medRxiv* server.
A new study discusses risk factors for the failure of seroconversion following full vaccination with the COVID-19 Pfizer vaccine.
In a paper, the vaccine-induced cellular and immune response of MS patients receiving a range of therapies are assessed.
Researchers in the UK have conducted a large population-based study showing that people with immune-mediated inflammatory diseases (IMIDs) appear to be at an increased risk of serious outcomes from coronavirus disease 2019 (COVID-19).
Burkitt lymphoma (BL) is a highly aggressive form of non-Hodgkin lymphoma (NHL) that comes in three different variants: endemic, immunodeficiency-associated, and sporadic. Of these variants, sporadic BL is most commonly found outside malaria-endemic countries and typically seen in young adults.
A study published on medRxiv* preprint server reported the over-time changes in the ability of the serum to activate platelets in vitro.
A recent study conducted at the Medical University of Graz, Austria, has revealed that the number of naïve B cells in the blood could independently predict the magnitude of immune response induced by coronavirus disease 2019 (COVID-19) vaccines in immunocompromised patients. The study is currently available on the medRxiv* preprint server.
A study measured neutralization of SARS-CoV-2 and vaccine responses in immunocompromised patients with systemic inflammatory diseases.
A recent study discusses the clinical characteristics and outcomes of patients with SARDs who were previously vaccinated against SARS-CoV-2.
A recent study in Colorado used real-world data to evaluate if individuals with chronic conditions have reduced antibody response to COVID-19 mRNA vaccines. The study investigated whether some medical conditions may impact antibody response to the mRNA vaccines.
Shuo Ma, MD, '00 PhD, associate professor of Medicine in the Division of Hematology and Oncology, was co-first author of the clinical trial published in Blood.
Researchers from Switzerland recently investigated humoral and cell-mediated immune responses to mRNA-based vaccines in patients undergoing treatment with CD20-B-cell depleting agents for autoimmune diseases, transplantation, or malignancy.
The American College of Rheumatology, in partnership with the Vasculitis Foundation (VF), released three new guidelines for the treatment and management of systemic vasculitis.